- Trial phase
- Preclinical / IND-enabling
- Time to market
- Preclinical/IND-enabling stage; likely years away from any potential approval if development proceeds.
- Why 2/10
- No hard, dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for TSC-303-A02 in the next ~12 months; the drug is a preclinical/IND-enabling candidate within a pipeline that was radically restructured in September 2026, and the company is focused on survival (reverse split vote, cash runway into Q4 2027).
TSC-303-A02 is an early-stage, preclinical candidate in TScan's new in vivo solid tumor pipeline. The next meaningful event would be an IND filing, which has not been publicly dated. The company's near-term binary is the November 20, 2026 shareholder vote on a reverse stock split to regain Nasdaq compliance. Watch for partnership announcements that could fund further development of the in vivo platform.
Price Chart
Executive Summary
TSC-303-A02 is a preclinical-stage in vivo TCR-T cell therapy candidate from TScan Therapeutics (TCRX), a micro-cap biotech that underwent a severe restructuring in September 2026. The company cut 75% of its workforce, paused its lead Phase 3 heme malignancy program (TSC-101), and pivoted entirely to early-stage in vivo solid tumor programs targeting PRAME and MAGE-A4. TSC-303-A02 is one of these candidates, still in IND-enabling studies with no clinical data, no regulatory filings, and no dated catalyst. The stock trades around $0.16 with a ~$11.5M market cap and faces a Nasdaq delisting risk. The drug is too early to evaluate on clinical merit and represents a small part of a distressed company's long-shot pivot.
How It Works
TSC-303-A02 is an in vivo-engineered T cell receptor (TCR) T cell therapy designed to target solid tumors. Unlike traditional cell therapies that are manufactured outside the body, this approach aims to engineer a patient's own T cells inside the body to recognize and attack cancer cells expressing specific tumor antigens (likely PRAME or MAGE-A4).
Trial Status
TScan announced in its November 12, 2026 Q3 update that it is advancing PRAME- and MAGE-A4-targeted in vivo TCR-T candidates through IND-enabling studies. TSC-303-A02 appears to be one of these early-stage solid tumor candidates. No clinical trials have been initiated.
The Two-Sided Case
Upcoming Catalysts
- November 20, 2026: Special shareholder meeting to vote on reverse stock split (1:2 to 1:50) to regain Nasdaq minimum bid price compliance.
- IND filing for in vivo solid tumor candidates (PRAME/MAGE-A4) -- no date announced.
- Potential partnership or licensing deal to fund the in vivo platform.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TScan Therapeutics, Inc. 8-K TCRX ·Originating report